Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. SRT for Oligoprogression in Metastatic RCC Patients Receiving TKI Therapy
  2. Activity of Cabozantinib in Pretreated Patients With mRCC With Sarcomatoid Differentiation
  3. Initial Treatment Choice in Metastatic RCC Prior to the Immunotherapy Era
  4. Camrelizumab + Famitinib in Patients With Advanced or Metastatic RCC
  5. Genetic Risk Assessment for Hereditary RCC
  6. Tumor Growth Rate Decline Despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC
  7. Definitive Radiotherapy for Extracranial Oligoprogressive Metastatic Renal Cell Carcinoma to Defer Systemic Therapy Escalation
  8. Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Patients With mRCC Receiving ICI
  9. Active Surveillance vs Immediate Systemic Treatment in Metastatic Renal Cell Carcinoma
  10. VHL Suppresses RAPTOR and Inhibits mTORC1 Signaling in ccRCC

Elsewhere

Recently Updated